Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04923893 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04923893 · ClinicalTrials.gov record · last posted 2026-07-06

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Study acronym: CARTITUDE-5
StatusActive, Not Recruiting
PhasePhase 3
Started2021-08-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).

Amendment record 66 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 66 times since 2021-06-10; most recent amendment 2026-07-02. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-09-10
Status change Recruiting→Active, Not Recruitingv42
2021-08-19
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT04923893
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 743 participants
Start Date 2021-08-19
Primary Completion 2029-02-14 (estimated)
Study Completion 2036-09-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-06